Search research articles
Contact Us
Filters
Showing results (1-10 of 34) with videos related to
Page
of 4
Sort By:
The Lancet. Rheumatology
|
October 19, 2025
Revisiting safety and refining benefit of rituximab-belimumab combination for refractory SLE
Michael R Ehrenstein, Muhammad Shipa, Kashfia Chowdhury, et al.
Trials
|
June 14, 2020
Corneal cross-linking versus standard care in children with keratoconus - a randomised, multicentre, observer-masked trial of efficacy and safety (KERALINK): a statistical analysis plan
Kashfia Chowdhury, Caroline J Doré, Catey Bunce, et al.
Trials
|
July 18, 2020
Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan
Patrick Muller, Kashfia Chowdhury, Caroline Gordon, et al.
Trials
|
February 20, 2020
A randomised, multi-centre trial of total ankle replacement versus ankle arthrodesis in the treatment of patients with end stage ankle osteoarthritis (TARVA): statistical analysis plan
Patrick Muller, Simon S Skene, Kashfia Chowdhury, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
February 24, 2026
Ambroxol for Parkinson's Disease
Marco Toffoli, Elisa Menozzi, Kashfia Chowdhury, et al.
BMJ Open
|
September 14, 2019
A randomised, controlled, observer-masked trial of corneal cross-linking for progressive keratoconus in children: the KERALINK protocol
Kashfia Chowdhury, Caroline Dore, Jennifer M Burr, et al.
Cell Reports. Medicine
|
July 24, 2025
IgA2<sup>+</sup> B cells and IgA2 anti-dsDNA antibodies are selectively targeted by belimumab after rituximab therapy in systemic lupus erythematosus
Daniel McCluskey, Muhammad R A Shipa, Kashfia Chowdhury, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
November 10, 2016
Comparison of the impact of cancer between British and US long-term non-Hodgkin lymphoma survivors
Shah-Jalal Sarker, Sophia K Smith, Kashfia Chowdhury, et al.
BMJ Open
|
December 19, 2019
Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial
Alexis Jones, Patrick Muller, Caroline J Dore, et al.
Journal of Parkinson'S Disease
|
May 31, 2018
What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson's Disease: A Post Hoc Analysis
Dilan Athauda, Kate Maclagan, Natalia Budnik, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 34) with videos related to
Sort By:
Page
of 4
The Lancet. Rheumatology
|
October 19, 2025
Revisiting safety and refining benefit of rituximab-belimumab combination for refractory SLE
Michael R Ehrenstein, Muhammad Shipa, Kashfia Chowdhury, et al.
Trials
|
June 14, 2020
Corneal cross-linking versus standard care in children with keratoconus - a randomised, multicentre, observer-masked trial of efficacy and safety (KERALINK): a statistical analysis plan
Kashfia Chowdhury, Caroline J Doré, Catey Bunce, et al.
Trials
|
July 18, 2020
Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan
Patrick Muller, Kashfia Chowdhury, Caroline Gordon, et al.
Trials
|
February 20, 2020
A randomised, multi-centre trial of total ankle replacement versus ankle arthrodesis in the treatment of patients with end stage ankle osteoarthritis (TARVA): statistical analysis plan
Patrick Muller, Simon S Skene, Kashfia Chowdhury, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
February 24, 2026
Ambroxol for Parkinson's Disease
Marco Toffoli, Elisa Menozzi, Kashfia Chowdhury, et al.
BMJ Open
|
September 14, 2019
A randomised, controlled, observer-masked trial of corneal cross-linking for progressive keratoconus in children: the KERALINK protocol
Kashfia Chowdhury, Caroline Dore, Jennifer M Burr, et al.
Cell Reports. Medicine
|
July 24, 2025
IgA2<sup>+</sup> B cells and IgA2 anti-dsDNA antibodies are selectively targeted by belimumab after rituximab therapy in systemic lupus erythematosus
Daniel McCluskey, Muhammad R A Shipa, Kashfia Chowdhury, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
November 10, 2016
Comparison of the impact of cancer between British and US long-term non-Hodgkin lymphoma survivors
Shah-Jalal Sarker, Sophia K Smith, Kashfia Chowdhury, et al.
BMJ Open
|
December 19, 2019
Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial
Alexis Jones, Patrick Muller, Caroline J Dore, et al.
Journal of Parkinson'S Disease
|
May 31, 2018
What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson's Disease: A Post Hoc Analysis
Dilan Athauda, Kate Maclagan, Natalia Budnik, et al.
Page
of 4